Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer

[1] Hansen HH(1992)Management of small-cell cancer of the lung Lancet 339 846-849

[2] Sundstrom S(2002)Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years’ follow-up J Clin Oncol 20 4665-4672

[3] Bremnes RM(2005)Chemotherapy strategies in the treatment of small cell lung cancer Anticancer Drugs 16 361-372

[4] Kaasa S(2002)Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer N Engl J Med 346 85-91

[5] Aasebo U(1999)Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer J Clin Oncol 17 658-667

[6] Hatlevoll R(1998)Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer Lancet 352 1413-1418

[7] Dahle R(1996)Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer J Clin Oncol 14 2540-2545

[8] Boye N(1997)Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning Cancer Res 57 5100-5106

[9] Wang M(1997)Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance Cancer Res 57 1516-1522

[10] Vigander T(1998)CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein Br J Cancer 77 359-365

[1] Hansen HH(1992)Management of small-cell cancer of the lung Lancet 339 846-849

[2] Sundstrom S(2002)Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years’ follow-up J Clin Oncol 20 4665-4672

[3] Bremnes RM(2005)Chemotherapy strategies in the treatment of small cell lung cancer Anticancer Drugs 16 361-372

[4] Kaasa S(2002)Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer N Engl J Med 346 85-91

[5] Aasebo U(1999)Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer J Clin Oncol 17 658-667

[6] Hatlevoll R(1998)Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer Lancet 352 1413-1418

[7] Dahle R(1996)Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer J Clin Oncol 14 2540-2545

[8] Boye N(1997)Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning Cancer Res 57 5100-5106

[9] Wang M(1997)Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance Cancer Res 57 1516-1522

[10] Vigander T(1998)CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein Br J Cancer 77 359-365